The financials
Regeneron Pharmaceuticals by the numbers
Regeneron Pharmaceuticals (REGN) reported revenue of $4.29B in Q2 2026 (quarter ended June 30, 2026), up 17% from the same quarter a year earlier. That came with net income of $1.30B (30% of revenue). For the full year FY2025, revenue was $14.3B (+1.0% year on year) and net income $4.50B. Its largest product in 2026-Q2 was Share Of Profit Losses at $2.03B, 50% of the disclosed total, just ahead of EYLEAHD at 15%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $4.29B | $3.68B | +17% |
| Operating income | $1.29B | $1.08B | +20% |
| Net income | $1.30B | $1.39B | −6.8% |
| Diluted EPS | $12.23 | $12.81 | −4.5% |
| Product | Revenue | Share |
|---|---|---|
| Share Of Profit Losses | $2.03B | 50% |
| EYLEAHD | $596M | 15% |
| Eylea Net Product Sales | $412M | 10% |
| LIBTAYO Net Product Sales | $343M | 8.5% |
| Product And Service Other | $193M | 4.8% |
| Reimbursement Of Commercialization Related Expenses | $189M | 4.7% |
| Reimbursement For Manufacturing Of Commercial Supplies | $142M | 3.5% |
| Praluent Net Product Sales | $75M | 1.8% |
| Evkeeza | $53M | 1.3% |
| Lynozyfic | $17M | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $4.03B (+21%)
Share Of Profit Losses grew +59% year on yearEylea Net Product Sales -45% year on year
Segment Latestquarter on quarteryear on year
- Share Of Profit Losses$2.03B$2.03BQoQ +40%year on year +59%+40%+59%
- EYLEAHD$596.3M$596.3MQoQ +27%year on year +52%+27%+52%
- Eylea Net Product Sales$412.2M$412.2MQoQ -13%year on year -45%-13%-45%
- LIBTAYO Net Product Sales$342.6M$342.6MQoQ +20%year on year +38%+20%+38%
- Product And Service Other$193.3M$193.3MQoQ +13%year on year +5.1%+13%+5.1%
- Reimbursement Of Commercialization Related Expenses$188.8M$188.8MQoQ +2.6%year on year -2.7%+2.6%-2.7%
- Reimbursement For Manufacturing Of Commercial Supplies$141.7M$141.7MQoQ -8.2%year on year -12%-8.2%-12%
- Praluent Net Product Sales$74.7M$74.7MQoQ +12%year on year +14%+12%+14%
- Evkeeza$53.3M$53.3MQoQ +17%year on year +29%+17%+29%
- Lynozyfic$16.5M$16.5MQoQ +47%year on year -+47%-
- ELYEAHD And EYLEA--QoQ -year on year ---
- ELYEAHD--QoQ -year on year ---
- Inmazeb--QoQ -year on year ---
- Other Products$0.00$0.00QoQ -100%year on year --100%-
- Regenerons Obligation Of Research And Development Expenses Net Of Reimbursement Of Research And Development Expenses−$600.0K−$600.0KQoQ -160%year on year --160%-
- Reimbursement Of Research And Development Expenses Net Of Obligation For Share Of RD Expenses−$19.4M−$19.4MQoQ -year on year ---